Latest News
Search News
Overcoming drug resistance in breast cancer
28th October 2021
In recognition of Breast Cancer Awareness Month, we spoke with Dr Ioanna Keklikoglou, Lecturer and Group Leader in the Centre for Tumour Microenvironment at Barts Cancer Institute, Queen Mary University of London. Dr Keklikoglou’s research focuses on understanding the molecular and cellular mechanisms that control resistance to anti-cancer therapies in breast cancer.
Read more
BCI research features in new Science Museum Group exhibition on cancer
25th October 2021
A research project led by Professor Fran Balkwill from Barts Cancer Institute at Queen Mary University of London features in a world-first free exhibition exploring the revolution in science that is transforming cancer care.
Read more
Celebrating the work of our PhD students
15th October 2021
On 28th September, we held our annual PhD Day – an event that celebrates the work of the postgraduate research students at the Barts Cancer Institute, Queen Mary University of London.
Read more
OPTIMA: Improving treatment for cancer patients through artificial intelligence
12th October 2021
Professors Claude Chelala and Louise Jones from Barts Cancer Institute, Queen Mary University of London, are part of a €21.3 million public-private research programme that will seek to use artificial intelligence to improve care for patients with prostate, breast and lung cancer.
Read more
Location is key: Understanding RNA localisation in cancer
4th October 2021
Dr Faraz Mardakheh has received a project grant from the Medical Research Council, part of UK Research and Innovation, to investigate how RNA localisation becomes dysregulated during cancer progression.
Read more
Mapping the emergence of treatment resistance in leukaemia
28th September 2021
Research led by Barts Cancer Institute, Queen Mary University of London, has identified a new role for a group of cells called adipocytes in contributing to treatment resistance in a type of leukaemia. Published in Nature Communications, the findings broaden the understanding of resistance pathways in blood cancer cells, which is critical for developing novel treatment strategies to improve outcomes for people with leukaemia.
Read more